

Maria Arechederra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4708070/maria-arechederra-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

469
citations

11
h-index

20
g-index

37
ext. papers

701
ext. citations

8.3
avg, IF

3.74
L-index

#	Paper	IF	Citations
31	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. <i>Gut</i> , 2021 , 70, 388-400	19.2	21
30	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 73, 2380-2396	11.2	3
29	Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. <i>Cancers</i> , 2021 , 13,	6.6	12
28	The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation. <i>Nucleic Acids Research</i> , 2021 , 49, 8592-8609	20.1	0
27	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. <i>Gut</i> , 2021 ,	19.2	5
26	ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021 , 74, 893-906	13.4	9
25	Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4 β Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage. <i>Hepatology</i> , 2021 , 74, 2791-2807	11.2	2
24	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. <i>Cancers</i> , 2020 , 12,	6.6	1
23	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. <i>Cancers</i> , 2020 , 12,	6.6	15
22	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020 , 1,	1.3	5
21	Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
20	Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. <i>JHEP Reports</i> , 2020 , 2, 100167	10.3	27
19	Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?. <i>Cells</i> , 2020 , 9,	7.9	7
18	C3G Is Upregulated in Hepatocarcinoma, Contributing to Tumor Growth and Progression and to HGF/MET Pathway Activation. <i>Cancers</i> , 2020 , 12,	6.6	2
17	Chromatin dynamics during liver regeneration. <i>Seminars in Cell and Developmental Biology</i> , 2020 , 97, 38-46	7.5	3
16	Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins. <i>Nucleic Acids Research</i> , 2019 , 47, 3450-3466	20.1	22
15	Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography. <i>IScience</i> , 2019 , 21, 68-83	6.1	5

14	New warning signs on the road: 5-hydroxymethylcytosine-based liquid biopsy for the early detection of hepatocellular carcinoma. <i>Gut</i> , 2019 , 68, 2103-2104	19.2	3
13	Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis. <i>Journal of Hepatology</i> , 2019 , 70, 470-482	13.4	6
12	TWEAK promotes migration and invasion in MEFs through a mechanism dependent on ERKs activation and Fibulin 3 down-regulation. <i>Journal of Cellular Physiology</i> , 2018 , 233, 968-978	7	
11	Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer. <i>Nature Communications</i> , 2018 , 9, 3164	17.4	80
10	Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 84	5.2	9
9	Fibroblast growth factors 19 and 21 in acute liver damage. <i>Annals of Translational Medicine</i> , 2018 , 6, 2573.2	3.2	8
8	A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases. <i>Hepatology</i> , 2017 , 66, 1644-1661	11.2	11
7	Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells. <i>Oncotarget</i> , 2016 , 7, 74747-74767	3.3	10
6	C3G knock-down enhances migration and invasion by increasing Rap1-mediated p38 β activation, while it impairs tumor growth through p38 β independent mechanisms. <i>Oncotarget</i> , 2016 , 7, 45060-45078	3.3	16
5	p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: role in migration and invasion. <i>Journal of Biological Chemistry</i> , 2015 , 290, 4383-97	5.4	19
4	Met signaling in cardiomyocytes is required for normal cardiac function in adult mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 2204-15	6.9	21
3	C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012 , 1823, 1366-77	4.9	9
2	p38 β mediates cell survival in response to oxidative stress via induction of antioxidant genes: effect on the p70S6K pathway. <i>Journal of Biological Chemistry</i> , 2012 , 287, 2632-42	5.4	99
1	C3G down-regulates p38 MAPK activity in response to stress by Rap-1 independent mechanisms: involvement in cell death. <i>Cellular Signalling</i> , 2010 , 22, 533-42	4.9	22